Nottingham, England, United Kingdom BioCity Group is the famous Corporate Investor, which was founded in 2002. The venture was found in Europe in United Kingdom. The main department of described Corporate Investor is located in the Nottingham.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Quality Assurance, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight NuVision.
The high activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of 1 - 5 millions dollars.
The typical case for the fund is to invest in rounds with 3 participants. Despite the BioCity Group, startups are often financed by Mercia Fund Managers, University of Nottingham, Pitch@Palace. The meaningful sponsors for the fund in investment in the same round are University of Nottingham, UCB Ventures, MEIF Proof-of-Concept & Early Stage Fund.
Related Funds
| Fund Name | Location |
| Anheuser-Busch InBev | New York, New York, United States |
| China Great Wall Asset Management | Beijing, Beijing, China |
| DeFi Alliance | - |
| Encourage Capital | New York, New York, United States |
| Freedom Communications | California, Santa Ana, United States |
| Hangzhou Shengdoushi Shengwu Keji Youxian Gongsi | China, Hangzhou, Zhejiang |
| Koor Corporate Venture Capital | Israel, Tel Aviv, Tel Aviv District |
| Shanghai Junshi Biosciences | China, Shanghai |
| Vogabakki | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
NanoSyrinx | $8M | 19 Jul 2021 | Coventry, England, United Kingdom | ||
Kinomica | $5M | 14 Dec 2020 | United Kingdom, England | ||
Rinri Therapeutics | $1M | 20 May 2019 | Massachusetts, United States | ||
GENXT | $68K | 24 Jan 2019 | - |
– Maxwellia is an Alderley Park, UK-based self-care company.
– The company raised £3.2m in funding led by Praetura Ventures with participation from the Future Fund, Catapult Ventures, Alderley Park Ventures and Biocity along with individual and angel investors.
– The new investment will be used to scale up the manufacture and rollout of drugs following MHRA approval.
– Maxwellia’s chief executive Anna Maxwell is a pharmacist with over 20 years’ experience.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
NanoSyrinx | $8M | 19 Jul 2021 | Coventry, England, United Kingdom | ||
Kinomica | $5M | 14 Dec 2020 | United Kingdom, England | ||
Rinri Therapeutics | $1M | 20 May 2019 | Massachusetts, United States | ||
GENXT | $68K | 24 Jan 2019 | - |
